WO2023012516 - COMPOSITIONS AND METHODS RELATED TO BLOOD-BRAIN BARRIER PENETRATION
National phase entry:
Publication Number
WO/2023/012516
Publication Date
09.02.2023
International Application No.
PCT/IB2022/000444
International Filing Date
02.08.2022
Title **
[English]
COMPOSITIONS AND METHODS RELATED TO BLOOD-BRAIN BARRIER PENETRATION
[French]
COMPOSITIONS ET MÉTHODES SE RAPPORTANT À LA PÉNÉTRATION D'UNE BARRIÈRE HÉMATO-ENCÉPHALIQUE
Applicants **
INSIGHTEC LTD.
P.o. Box 2059
39120 Tirat Carmel, IL
SUNNYBROOK RESEARCH INSTITUTE
2075 Bayview Avenue
Toronto, ON M4N 3M5, CA
Inventors
ACHROL, Achal, Singh
c/o Insightec, Ltd.
801 Brickell Ave., Suite 1600
Miami, FL 33131, US
LIPSMAN, Nir
c/o Sunnybrook Research Institue
2075 Bayview Avenue
Toronto, ON M4N 3M5, CA
MENG, Ying
c/o Sunnybrook Research Institue
2075 Bayview Avenue
Toronto, ON M4N 3M5, CA
ALIKACEM, Nadir
c/o Insightec, Ltd.
801 Brickell Ave., Suite 1600
Miami, FL 33131, US
Priority Data
63/229,865
05.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3050 | |
| EPO | Filing, Examination | 40601 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 14710 |
Total: 59525 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure is directed to methods related to the delivery of antibodies targeting Her2 across the blood-brain barrier.[French]
La divulgation concerne des méthodes liées à l'administration d'anticorps ciblant Her2 à travers la barrière hémato-encéphalique.